The Uncomfortable Truth About Funding Rare Disease Treatment

There’s a pay problem in the quest to help those with rare diseases. The uncomfortable truth behind the breakthroughs is that cures only get funded at scale when the economics work. The hidden kingmaker is not the drug company, it’s insurance. RA Capital Managing Partner Peter Kolchinsky and Aradigm Health CEO Dr. Will Shrank talk about why this happens, what needs to change, and the new models being developed to flip the problem on its head.